Company Name Zavante Therapeutics
Mailing Address 12670 High Bluff Dr. San Diego, CA 92130 USA
Company Description We are passionately committed to our mission to improve patients’ lives by identifying, developing and commercializing novel therapeutics addressing significant unmet medical needs in the hospital setting.
Proceeds Purposes The company has closed a $45 million Series A financing, consisting of $35 million from new investors and $10 million from the conversion of outstanding convertible notes. Proceeds from the financing will be used for the development of the Company’s lead product candidate, ZTI-01 (fosfomycin for injection), an injectable antibiotic with a differentiated mechanism of action designed for use in the hospital setting. In the second quarter of 2016, Zavante plans to initiate the ZEUS Study, a single pivotal clinical trial for ZTI-01, a first-in-class broad spectrum IV antibiotic under development to treat multidrug resistant (MDR) pathogens.